2021
Effects of Delayed Radical Prostatectomy and Active Surveillance on Localised Prostate Cancer—A Systematic Review and Meta-Analysis
Chan V, Tan W, Asif A, Ng A, Gbolahan O, Dinneen E, To W, Kadhim H, Premchand M, Burton O, Koe J, Wang N, Leow J, Giannarini G, Vasdev N, Shariat S, Enikeev D, Ng C, Teoh J. Effects of Delayed Radical Prostatectomy and Active Surveillance on Localised Prostate Cancer—A Systematic Review and Meta-Analysis. Cancers 2021, 13: 3274. PMID: 34208888, PMCID: PMC8268689, DOI: 10.3390/cancers13133274.Peer-Reviewed Original ResearchNeoadjuvant hormonal therapyDelayed radical prostatectomyHigh-risk patientsRandomised controlled trialsRadical prostatectomyImmediate RPOncological outcomesCancer-specific survivalIntermediate-risk patientsMeta-analysisNewcastle-Ottawa ScaleDelayed RPIntermediate-riskNon-randomised controlled studiesRisk of biasOverall survivalHormone therapyWatchful waitingExpectant managementActive surveillanceCancer surgeryPathological outcomesNewcastle-OttawaLow riskObservational study
2020
Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria
Woldu S, Ng C, Loo R, Slezak J, Jacobsen S, Tan W, Kelly J, Lough T, Darling D, van Kessel K, de Jong J, van Criekinge W, Shariat S, Hiar A, Brown S, Boorjian S, Barocas D, Svatek R, Lotan Y. Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria. Journal Of Urology 2020, 205: 1387-1392. PMID: 33356483, DOI: 10.1097/ju.0000000000001550.Peer-Reviewed Original ResearchConceptsIncidence of bladder cancerBladder cancerHigh-risk groupRisk groupsRisk strataCancer incidenceDegree of hematuriaHigh-risk patientsRisk stratification systemAmerican Urological AssociationEvaluation of patientsMultinational cohort studyRisk-stratified approachBladder cancer incidenceHematuria patientsClinically meaningful categoriesGross hematuriaUrologic evaluationIntermediate riskProspective registryRisk patientsContemporary patientsSmoking historyUrological AssociationHematuria
2019
Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis
Jubber I, Shariat S, Conroy S, Tan W, Gordon P, Lotan Y, Messing E, Stenzl A, Rhijn B, Kelly J, Catto J, Cumberbatch M. Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis. European Urology 2019, 77: 583-598. PMID: 31791622, DOI: 10.1016/j.eururo.2019.10.010.Peer-Reviewed Original ResearchConceptsNon-visible haematuriaUpper tract urothelial carcinomaMeta-analysisSystematic reviewKidney cancerSystematic review of original articlesUrological cancersRisk of cancerIncidence of cancerReview of original articlesCancer detection rateRe-evaluation of patientsPublic health implicationsBladder cancerNarrative synthesisDiagnosis of BCInclusion criteriaMeta-analysesCigarette smokingHealth implicationsDiagnosis of bladder cancerMale sexEstimated riskHigh-risk patientsGroup of individualsMixed‐methods approach to exploring patients’ perspectives on the acceptability of a urinary biomarker test in replacing cystoscopy for bladder cancer surveillance
Tan W, Teo C, Chan D, Heinrich M, Feber A, Sarpong R, Allan J, Williams N, Brew‐Graves C, Ng C, Kelly J, Khetrapal P, ridhar A, Baker H, Ocampo F, Whotton N, Dent K, Pearson S, Hatton J, Newton M, Heeney E, Green K, Evans S, Rogers M, Dann A, Cook J, Cornwell M, Mills R, Knight H, Maher S, Rane A, Thomas S, Reyner S, Vallejera G, Adeniran P, Masood S, Ridgway S, Coulding M, Savill H, Mccormick J, Clark M, Collins G, Jewers K, Keith S, Bowen G, Hargreaves J, Riley K, Srirangam S, Mistry R, Chadwick J, Cocks S, Hull R, Loftus A, Dawson L, Roberts H, Main C, Jain S, Waymont C, Rogers J, Grant A, Carter V, Heap H, Lomas C, Cooke P, Baird Y, Moore S, Greenslade S, Margalef J, Chadbourn I, Harris M, Hicks J, Clitheroe P, Connolly S, Hodgkinson S, Haydock H, inclair A, Storr E, Cogley L, Natale S, Lovegrove W, Smith S, Smith K, Hewitt D, Sriram R, Atkinson K, Royle L, Madine J, MacLean K, Walsh J, Guerdette M, Hill M, Payne D, Power A, Cannon J, Devereaux L, Thompson A, Scarratt L, Hodgkiss T, Johnstone D, Johnson J, Allsop J, Rothwell J, Connolly K, Cherian J, Wardle H, Wilson D, Bayles A, Pelluri S, Pati J, Gherman A, Scott C, Madaan S, Taylor A, Edmunds E, Moore J, Rees A, Williams S, Caddy S, Dukes S, Goffe A, Buckhorn K, Nichols L, Acher P, Baillie K, Middleton K, Proctor C, Cresswell J, Chilvers A, Cain M, Vaux A, Watson D, Bradfield S, Gregory H, Mostafid H, Kehoe L, Drakeley S, Davies A, Williamson L, Krishnan R, Lunt N, Hill P, Burns H, Townley B, Wilkinson L, Wassall H, Hunt J, Holbrook B, Stancombe L, Morrison J, Vankoutrik L, Misra S, Fossey G, Richards A, Mcdonald K, Henderson A, Fennelly R, Tribbeck M, Ames K, Borwell J, Kotze M, Beesley K, Rennie K, Porter T, Gipson A, Piper L, Bailey L, Chrisopoulou A, Slevin K, McCartin F, Warburton H, Hathaway‐Lees S, Whetton K, Delves G, Day A, Bankole T, Broadhead S, Malde S, Oblak M, Ellis D, Bishara S, Barias‐Lara T, Donkov I, Thatcher H, Morris M, Culmsee C, Menzies H, Bartlett C, Cutting C, O'Brien N, Jannapureddy R, Kelkar A, Fitzgerald J, Longhurst S, Worth C, Peracha M, Mzazi S, Poile C, Griffiths L, Cook A, Barber N, Brar N, lty A, Zelhof B, Blades R. Mixed‐methods approach to exploring patients’ perspectives on the acceptability of a urinary biomarker test in replacing cystoscopy for bladder cancer surveillance. BJU International 2019, 124: 408-417. PMID: 30694612, PMCID: PMC6767410, DOI: 10.1111/bju.14690.Peer-Reviewed Original ResearchConceptsMinimally acceptable sensitivityAdverse eventsMixed-methods approachUrine biomarkersUrinary biomarkersProspective multicentre observational studyUrinary biomarker testsUrinary tract symptomsHome to hospitalAssociated with adverse eventsUrinary tract infectionHigh-risk patientsMulticentre observational studySensitivity of cystoscopyBladder cancer surveillanceDiagnosis of cancerSemi-structured interviewsPrevalence of haematuriaPatient experiencePatient perspectivePatients' viewsCancer surveillanceTract infectionsUrine biomarker studiesPatient demographics
2018
BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)
Kelly J, Tan W, Porta N, Mostafid H, Huddart R, Protheroe A, Bogle R, Blazeby J, Palmer A, Cresswell J, Johnson M, Brough R, Madaan S, Andrews S, Cruickshank C, Burnett S, Maynard L, Hall E, Investigators O. BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). European Urology 2018, 75: 593-601. PMID: 30279015, DOI: 10.1016/j.eururo.2018.09.020.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravesicalAgedAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBCG VaccineCarcinoma, Transitional CellCardiovascular DiseasesCelecoxibCyclooxygenase 2 InhibitorsDisease ProgressionDouble-Blind MethodFemaleHumansMaleMiddle AgedMitomycinNeoplasm Recurrence, LocalNeoplasm StagingQuality of LifeRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited KingdomUrinary Bladder NeoplasmsConceptsNon-muscle-invasive bladder cancerHigh-risk non-muscle-invasive bladder cancerRisk of recurrenceIncreased risk of cardiovascular eventsRisk of cardiovascular eventsTime to recurrenceCardiovascular eventsNMIBC patientsBladder cancerStandard treatmentPhase III placebo-controlled trialIntermediate-risk non-muscle-invasive bladder cancerNon-muscle-invasive bladder cancer patientsIncreased riskPatients treated with celecoxibWeekly mitomycin C instillationsMitomycin C instillationAdjuvant intravesical therapyRecurrence-free rateMedian follow-upPlacebo-controlled trialTransitional cell carcinomaHigh-risk patientsCyclo-oxygenase 2 inhibitorsIntravesical therapy